Getting started with in-house development: storyboarding
Introducing our three-part blog series on getting started with in-house development. In this series, we’re…
Certara2020年2月21日
Getting started with in-house development: how does it work?
Introducing our three-part blog series on getting started with in-house development. In this series, we’re…
Certara2020年2月10日
Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development
Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…
Certara2019年12月19日
Patient Engagement and Patient Centricity Series Part II: Types of Patient Advocates
Nirpal Virdee, Synchrogenix’s Global Head of Transparency and Disclosure recently sat down with Trishna Bharadia,…
Certara2019年11月11日
ICER’s Unsupported Drug Price Increase Report: An Analysis
We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported…
Certara2019年10月24日
Health Canada PRCI Guiding Principles and Observations
Health Canada released guidance on 2019年3月12日 pertaining to its Public Release of Clinical…
Certara2019年9月16日
Common Questions about Define-XML and the Stylesheet
In this blog, we answer common questions about Define-XML and the Stylesheet, including all you…
Certara2019年8月22日
Trends for Market Access, HEOR, and Real World Evidence
This blog reviews trends for using health economics and outcomes research and real-world evidence to…
Certara2019年5月10日
Real World Evidence Marches Forward in Drug Development
The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…
Certara2019年3月20日
Managing Immunogenicity Using Quantitative Systems Pharmacology
The Challenge of Immunogenicity in Biologics Drug Development Biologic drug development is a rapidly evolving…
Certara2019年2月22日
